Patients With Necrotizing Skin and Soft Tissue Infections Managed Within the SURFAST Care Pathway. (SURFAST)

Patients With Necrotizing Skin and Soft Tissue Infections Managed Within the Great Paris Area SURFAST Care Pathway: a Prospective, Multicenter Cohort Study.

Necrotising soft-tissue infections (NSTIs) are rare and life-threatening skin and soft tissue infections requiring urgent combined medical and surgical management in specialist centres. At Assistance Publique-Hôpitaux de Paris, a multidisciplinary reference network called the SURFAST consortium has been established. This network includes experts in the management of NSTIs, such as intensivists, dermatologists, infectious disease physicians, paediatricians, surgeons, and microbiologists. The consortium manages all NSTI cases referred from the greater Paris area, a large region of France with a population exceeding 12 million.

The SURFAST network comprises care pathways enabling the management of adult and paediatric patients with abdomino-perineal, limb, and cervico-facial NSTIs. All patients managed within this care pathway are included in a prospective, multicentre cohort study. This study examines factors associated with mortality at day 90, long-term sequelae, quality of life, and indicators of the quality of care.

Study Overview

• Status: Not yet recruiting
• Conditions: Necrotizing Soft-tissue Infections

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

• Study Contact: Name: Nicolas DE PROST, PU-PH; Phone Number: +33 1 45 17 86 37; Email: nicolas.de-prost@aphp.fr
• Study Contact Backup: Name: Thomas URBINA, Dr; Email: Tomas.urbina@aphp.fr

Study Locations

• France
  • Île-de-France Region
    • Créteil, Île-de-France Region, France, 94000
      • Hôpital Henri Mondor, 1 rue Gustave Eiffel,
      • Contact: Nicolas DE PROST, PU-PH; Phone Number: +33 1 45 17 86 37; Email: nicolas.de-prost@aphp.fr
      • Contact: Thomas URBINA, Dr; Email: Tomas.urbina@aphp.fr
      • Principal Investigator: Nicolas de prost, PH PH

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients (adults and children) with a suspected or confirmed necrotizing soft-tissue infections (NSTI) managed within the SURFAST care pathway.

Description

Inclusion Criteria:

• All patients (adults and children, irrespective of age) managed for suspected or surgically confirmed necrotizing soft-tissue infections (NSTI) • Consent to participate in the study

Exclusion Criteria:

• Patient or legal representative's refusal to participate in the study

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort
- Adult / limb and abdomino-perineal
- Adult / cervico-facial
- Pediatric

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
mortality	If the patient is still hospitalized, an on-site visit will be conducted; otherwise, the patient or their relative will be contacted by telephone by an investigator or a study coordinator	90 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
hospital mortality	vital status measured at hospital discharge	at hospital discharge and within 60 days of hospital admission
time from hospital admission to first surgical debridement	time period measured in hours between first hospital admission and first surgical debridement	within the first 72 hours of hospital admission
functional outcome and quality of life	measured using the Activity of Daily Living (ADL) and the EQ-5D-5L (EuroQol) French version scores	day 90 post-admission
amputation rate	toe or limb amputation performed	day 90
annual case volume per centre	number of NSTI cases managed per year in each centre participating in the SURFAST network	123 months
bacteriological documentation	bacterial documentation of NSTIs obtained from blood cultures or cultures of operative tissue samples.	At the time of blood culture collection or operative tissue sampling

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Estimated): March 1, 2026
• Primary Completion (Estimated): June 1, 2036
• Study Completion (Estimated): June 1, 2036

Study Registration Dates

• First Submitted: January 14, 2026
• First Submitted That Met QC Criteria: February 10, 2026
• First Posted (Actual): February 18, 2026

Study Record Updates

• Last Update Posted (Actual): February 18, 2026
• Last Update Submitted That Met QC Criteria: February 10, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Necrotizing soft-tissue infections; necrotizing fasciitis; Skin and soft tissue necrotizing infections; SURFAST
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Fasciitis; Fasciitis, Necrotizing
• Other Study ID Numbers: APHP251357

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No